12:00 AM
Sep 28, 2015
 |  BC Week In Review  |  Clinical News  |  Clinical Status

TGR-1202: Phase I/II started

TG Therapeutics began an open-label, U.S. Phase I/II trial to evaluate oral TGR-1202, IV ublituximab ( TG-1101) and IV Keytruda pembrolizumab in about 12 patients. TG Therapeutics has...

Read the full 131 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >